Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia
IRCT20220117053743N3Phase 3Not yet recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minoxidil in androgenetic alopecia (AGA) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in hair density, Change in hair shaft diameter and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
minoxidil
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT20220117053743N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220117053743N3.